Featuring news, events and industry trends
Applications Now Open: Westchester County Biosciences Accelerator

Interested in launching a bioscience venture?

The Westchester County Biosciences Accelerator is a competitive entry, 6-month long program designed to provide entrepreneurship education and regional networking to seed-stage ventures preparing to build their teams and secure funds. Innovators with therapeutics, diagnostics, medical devices, research tools, digital health and materials technology breakthroughs are invited to apply. You do not need to have already formed a company to apply. The deadline to apply is October 25.
Westchester County Biosciences Accelerator:
October 12 Info Session

Join us for this virtual session and learn how to strengthen your application. Hear directly from screeners on how to improve your chance of admission.
REGEN-COV Cuts Viral Load within 7 Days in COVID-19 Patients

Tarrytown headquartered, Regeneron Pharmaceuticals (NSDQ:REGN) and Roche (OTCQX: RHHBY) are touting positive results from a Phase 2/3 study investigating the potential of REGEN-COV (casirivimab and imdevimab) antibody cocktail in hospitalized COVID-19 patients.

The study met its primary endpoint of reducing viral load within one week in seronegative patients needing low-flow or no supplemental oxygen. REGEN-COV, known as Ronapreve outside of the U.S., led to a 36% reduced risk of death by day 29 in the overall treatment population.

Roche has partnered with Regeneron (NSDQ: REGN) to help manufacture and distribute REGN-COV2, which Regeneron first developed.
Teladoc (TDOC) to Offer Remote Solutions for Canada Patients

Teladoc Health, Inc., based in Purchase, NY, recently announced that it has been delegated the role of a pre-qualified vendor by Canada Health Infoway in a bid to offer remote patient monitoring solution.

The selection has enabled Teladoc Health to continuously monitor and detect chronic and acute conditions of patients in the comfort of their homes. This helped the company in providing enhanced digital health solutions, which has been resulting in better health outcomes for patients across several provinces and territories of Canada. In fact, the move has aided the healthcare provider to cater to around 60% of the population in Canada.
Contrafect’s New Phase 2 Exebacase Data Presented at IDWeek Demonstrates Rapid Symptom Resolution Among Patients with Staphylococcus Aureus Bacteremia

Yonkers headquartered, ContraFect Corporation (Nasdaq:CFRX), a late clinical-stage biotechnology company focused on the discovery and development of biologic therapies for life-threatening, drug-resistant infectious diseases, announced new data from the Company’s Phase 2 study of exebacase demonstrating rapid symptom resolution among patients with Staphylococcus aureus (Staph aureus) bacteremia.
The oral data presentation, Exebacase Shows Rapid Symptom Resolution in a Phase 2 Study in Adult Patients with Staphylococcus aureus Bacteremia, demonstrated that exebacase, used in addition to standard of care antibiotics (SOCA), more rapidly resolved symptoms of Staph aureus bacteremia versus SOCA alone.
Staph aureus is a leading cause of infections in US healthcare facilities. Any Staph infection can be deadly. Staph aureus infections can be either methicillin-resistant (MRSA) or methicillin-susceptible (MSSA). MRSA infections are particularly difficult to treat because of their resistance to antibiotics, increasing virulence and patient comorbidities.

Have good news to share from
Westchester’s biosciences ecosystem?

Please let us know.

If you would like to continue receiving this weekly newsletter,
please sign up below. If you would like to contact us directly, click the Contact Us link.